Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 697-699

  Kosmidis, P A ^a   Mylonakis, N ^a   Fountzilas, G ^b   Samantas, E ^c   Athanasiadis, A ^b   Andreopoulou, E ^d   Pavlidis, N ^d   Skarlos, D ^c  

^a METAXA CANCER HOSPITAL   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c Saint Anargiri Cancer Hospital   (Greece)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Carboplatin; Chemotherapy; NSCLC; Paclitaxel

Indexed keywords

CARBOPLATIN; ONDANSETRON; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0030796490     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008268911935     Document Type: Article

References (10)

1. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4: 701-9.
2. Murphy WK, Fossella F, Winn RT et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J. Natl Cancer Inst 1993; 85: 384-8.
3. Bonomi P, Finkelstein D, Ruckdeschel J et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13.
4. Calvert AH, Newell DR, Gumbrell LA et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
5. Kosmidis P, Mylonakis N, Skarlos D et al. A comparative study of cisplatin and vinblastine vs. ifosfamide, cisplatin, and vinblastine in non-operable non-small cell lung cancer. Ann Oncol 1994; 5: 159-62.
6. Rowinski EK, Donehower RC. Paclitaxel (Taxol). N. Engl J Med 1995; 332: 1004-14.
7. Johnson HD, Paul MD, Hande KR et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 1996; 14: 2054-60.
8. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): A phase II toxicity, response and survival analysis (FCCC 93-624). J Clin Oncol 1995; 13: 1860-70.
9. Rowinski EK, Sartorins SE, Bowling MK et al. Paclitaxel on a three-hour schedule and carboplatin in non-small cell lung cancer. Use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 1995; 14: 354 (Abstr).
10. Hainsworth JD, Thompson DS, Greco FA et al. Paclitaxel by one-hour infusion. An active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609-14.